- cafead   Jul 13, 2023 at 10:33: AM
via Roche’s Phase III trial for Ocrevus (ocrelizumab) as a subcutaneous injection met its primary and secondary endpoints in patients with primary progressive and relapsing forms of multiple sclerosis (MS).
article source
article source